Thomas C. Ransohoff, M.S., Vice President and Principal Consultant, has over 25 years of experience in the biopharmaceutical industry. Mr. Ransohoff’s areas of expertise include development and scale-up of biopharmaceutical processes; separations and purification technologies; cGMP manufacturing; and management of technology-based start-up ventures.
Mr. Ransohoff is a co-founder of Tarpon Biosystems, Inc and of BioFlash Partners LLC, where he was President and CEO prior to the successful sale of BioFlash in 2010.
Before joining BPTC, Mr. Ransohoff was Vice President, Operations at TranXenoGen, Inc., responsible for operations and purification process development. Prior to that, he was Vice President, Bioseparations at Dyax Corp, where he was instrumental in managing a business unit to develop novel affinity separations products using phage display technology.
At Repligen, Mr. Ransohoff was Senior Director, Manufacturing, responsible for cGMP pilot plant operations, overseeing clinical supply for several biopharmaceutical product candidates as well as production of critical reagents such as Protein A for commercial sale.
He is a member of the Editorial Advisory Board of BioPharm Magazine and has served on a number of scientific and professional advisory boards.
Mr. Ransohoff has a Bachelor’s degree from MIT and a Master’s degree from the University of California, Berkeley, both in Chemical Engineering.